StreetInsider.com News Articles

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: 5AM Ventures VII, L.P.

Wed, 05 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260805/26876181.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Schwab Andrew J.

Wed, 05 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260805/26876121.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Young Richard A

Wed, 05 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26875815.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Maricich Yuri

Wed, 05 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26875801.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Gold Kelly

Wed, 05 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26875789.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Mandel-Brehm Josh

Wed, 05 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26875773.html

Camp4 Therapeutics closes second tranche of $100M private placement

Tue, 04 Aug 2026 07:00:27 -0400

Camp4 Therapeutics Corporation (Nasdaq: CAMP) announced the closing of the second tranche of a previously announced private placement, raising approximately $50.1 million in gross proceeds.

The second closing involved the issuance of 10,756,498 shares of common stock priced at $1.53 per share, 39,306 shares priced at $1.65 to certain directors, employees, and consultants, and 21,925,368 pre-funded warrants at $1.5299 each. The securities purchase agreement was originally dated September 9, 2025.

The company said it intends to use the net proceeds to advance CMP-002, its lead investigational antisense oligonucleotide therapeutic candidate targeting SYNGAP1-related disorder. Camp4 recently received clearance from Australia's Therapeutic Goods Administration

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Tue, 04 Aug 2026 07:00:00 -0400

Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the closing of the second tranche of its previously announced private placement pursuant to a securities purchase agreement, dated September 9, 2025, with certain institutional

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Tue, 04 Aug 2026 07:00:00 -0400

Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder

Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial

Mon, 27 Jul 2026 07:02:41 -0400

Camp4 Therapeutics Corporation (Nasdaq: CAMP) said it received clearance from Australia's Therapeutic Goods Administration (TGA) and a local Human Research Ethics Committee (HREC) to initiate a Phase 1/2 clinical trial of CMP-002, an investigational antisense oligonucleotide (ASO) therapy targeting SYNGAP1-related disorder.

SYNGAP1-related disorder is a rare genetic condition affecting more than 10,000 individuals in the United States. It is characterized by intellectual disability in all patients, epilepsy in approximately 85%, and severe behavioral problems in approximately 70%. No approved disease-modifying therapies currently exist for the condition.

CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA to increase gene expression and restore

Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial

Mon, 27 Jul 2026 07:02:41 -0400

CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA to increase gene expression and restore

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

Mon, 27 Jul 2026 07:00:00 -0400

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder

Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025

CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that it has received clearance from

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

Mon, 27 Jul 2026 07:00:00 -0400

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder

Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:05:00 -0400

CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:05:00 -0400

X4 Pharmaceuticals adds Kelly Gold to its board of directors

Wed, 01 Jul 2026 07:00:39 -0400

X4 Pharmaceuticals (Nasdaq: XFOR) announced the appointment of Kelly Gold to its board of directors, effective July 1, 2026. Gold will serve as an independent director and member of the Audit Committee, according to a press release from the company.

Gold currently serves as Chief Financial Officer at CAMP4 Therapeutics (Nasdaq: CAMP), where she oversees corporate finance and accounting, investor relations, and strategic financial planning. Before becoming CFO at CAMP4, she held roles in business development and finance at the same company.